Cargando…

Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy

An in vitro assay system using patient-derived tumor models represents a promising preclinical cancer model that replicates the disease better than traditional cell culture models. Patient-derived tumor organoid (PDO) and patient-derived tumor xenograft (PDX) models have been previously established...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Nobuhiko, Higa, Arisa, Hiyama, Gen, Tamura, Hirosumi, Hoshi, Hirotaka, Dobashi, Yuu, Katahira, Kiyoaki, Ishihara, Hiroya, Takagi, Kosuke, Goda, Kazuhito, Okabe, Naoyuki, Muto, Satoshi, Suzuki, Hiroyuki, Shimomura, Kenju, Watanabe, Shinya, Takagi, Motoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020396/
https://www.ncbi.nlm.nih.gov/pubmed/33841567
http://dx.doi.org/10.3892/ol.2021.12667
_version_ 1783674575128625152
author Takahashi, Nobuhiko
Higa, Arisa
Hiyama, Gen
Tamura, Hirosumi
Hoshi, Hirotaka
Dobashi, Yuu
Katahira, Kiyoaki
Ishihara, Hiroya
Takagi, Kosuke
Goda, Kazuhito
Okabe, Naoyuki
Muto, Satoshi
Suzuki, Hiroyuki
Shimomura, Kenju
Watanabe, Shinya
Takagi, Motoki
author_facet Takahashi, Nobuhiko
Higa, Arisa
Hiyama, Gen
Tamura, Hirosumi
Hoshi, Hirotaka
Dobashi, Yuu
Katahira, Kiyoaki
Ishihara, Hiroya
Takagi, Kosuke
Goda, Kazuhito
Okabe, Naoyuki
Muto, Satoshi
Suzuki, Hiroyuki
Shimomura, Kenju
Watanabe, Shinya
Takagi, Motoki
author_sort Takahashi, Nobuhiko
collection PubMed
description An in vitro assay system using patient-derived tumor models represents a promising preclinical cancer model that replicates the disease better than traditional cell culture models. Patient-derived tumor organoid (PDO) and patient-derived tumor xenograft (PDX) models have been previously established from different types of human tumors to recapitulate accurately and efficiently their tissue architecture and function. However, these models have low throughput and are challenging to construct. Thus, the present study aimed to establish a simple in vitro high-throughput assay system using PDO and PDX models. Furthermore, the current study aimed to evaluate different classes of anticancer drugs, including chemotherapeutic, molecular targeted and antibody drugs, using PDO and PDX models. First, an in vitro high-throughput assay system was constructed using PDO and PDX established from solid and hematopoietic tumors cultured in 384-well plates to evaluate anticancer agents. In addition, an in vitro evaluation system of the immune response was developed using PDO and PDX. Novel cancer immunotherapeutic agents with marked efficacy have been used against various types of tumor. Thus, there is an urgent need for in vitro functional potency assays that can simulate the complex interaction of immune cells with tumor cells and can rapidly test the efficacy of different immunotherapies or antibody drugs. An evaluation system for the antibody-dependent cellular cytotoxic activity of anti-epidermal growth factor receptor antibody and the cytotoxic activity of activated lymphocytes, such as cytotoxic T lymphocytes and natural killer cells, was constructed. Moreover, immune response assay systems with bispecific T-cell engagers were developed using effector cells. The present results demonstrated that in vitro assay systems using PDO and PDX may be suitable for evaluating anticancer agents and immunotherapy potency with high reproducibility and simplicity.
format Online
Article
Text
id pubmed-8020396
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-80203962021-04-10 Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy Takahashi, Nobuhiko Higa, Arisa Hiyama, Gen Tamura, Hirosumi Hoshi, Hirotaka Dobashi, Yuu Katahira, Kiyoaki Ishihara, Hiroya Takagi, Kosuke Goda, Kazuhito Okabe, Naoyuki Muto, Satoshi Suzuki, Hiroyuki Shimomura, Kenju Watanabe, Shinya Takagi, Motoki Oncol Lett Articles An in vitro assay system using patient-derived tumor models represents a promising preclinical cancer model that replicates the disease better than traditional cell culture models. Patient-derived tumor organoid (PDO) and patient-derived tumor xenograft (PDX) models have been previously established from different types of human tumors to recapitulate accurately and efficiently their tissue architecture and function. However, these models have low throughput and are challenging to construct. Thus, the present study aimed to establish a simple in vitro high-throughput assay system using PDO and PDX models. Furthermore, the current study aimed to evaluate different classes of anticancer drugs, including chemotherapeutic, molecular targeted and antibody drugs, using PDO and PDX models. First, an in vitro high-throughput assay system was constructed using PDO and PDX established from solid and hematopoietic tumors cultured in 384-well plates to evaluate anticancer agents. In addition, an in vitro evaluation system of the immune response was developed using PDO and PDX. Novel cancer immunotherapeutic agents with marked efficacy have been used against various types of tumor. Thus, there is an urgent need for in vitro functional potency assays that can simulate the complex interaction of immune cells with tumor cells and can rapidly test the efficacy of different immunotherapies or antibody drugs. An evaluation system for the antibody-dependent cellular cytotoxic activity of anti-epidermal growth factor receptor antibody and the cytotoxic activity of activated lymphocytes, such as cytotoxic T lymphocytes and natural killer cells, was constructed. Moreover, immune response assay systems with bispecific T-cell engagers were developed using effector cells. The present results demonstrated that in vitro assay systems using PDO and PDX may be suitable for evaluating anticancer agents and immunotherapy potency with high reproducibility and simplicity. D.A. Spandidos 2021-05 2021-03-22 /pmc/articles/PMC8020396/ /pubmed/33841567 http://dx.doi.org/10.3892/ol.2021.12667 Text en Copyright: © Takahashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Takahashi, Nobuhiko
Higa, Arisa
Hiyama, Gen
Tamura, Hirosumi
Hoshi, Hirotaka
Dobashi, Yuu
Katahira, Kiyoaki
Ishihara, Hiroya
Takagi, Kosuke
Goda, Kazuhito
Okabe, Naoyuki
Muto, Satoshi
Suzuki, Hiroyuki
Shimomura, Kenju
Watanabe, Shinya
Takagi, Motoki
Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy
title Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy
title_full Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy
title_fullStr Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy
title_full_unstemmed Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy
title_short Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy
title_sort construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020396/
https://www.ncbi.nlm.nih.gov/pubmed/33841567
http://dx.doi.org/10.3892/ol.2021.12667
work_keys_str_mv AT takahashinobuhiko constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT higaarisa constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT hiyamagen constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT tamurahirosumi constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT hoshihirotaka constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT dobashiyuu constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT katahirakiyoaki constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT ishiharahiroya constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT takagikosuke constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT godakazuhito constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT okabenaoyuki constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT mutosatoshi constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT suzukihiroyuki constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT shimomurakenju constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT watanabeshinya constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy
AT takagimotoki constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy